|
ZCCHC7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.99200722162641E-15 |
| Normal-vs-Stage2 |
2.66940003434968E-09 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
5.86986015349567E-12 |
| Stage1-vs-Stage2 |
2.729600E-01 |
| Stage1-vs-Stage3 |
3.239100E-03 |
| Stage1-vs-Stage4 |
6.303700E-02 |
| Stage2-vs-Stage3 |
3.461200E-01 |
| Stage2-vs-Stage4 |
7.454400E-01 |
| Stage3-vs-Stage4 |
5.096000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.71829999995321E-06 |
| Normal-vs-Asian |
3.6164999883681E-09 |
| Caucasian-vs-AfricanAmerican |
9.132000E-01 |
| Caucasian-vs-Asian |
3.908200E-01 |
| AfricanAmerican-vs-Asian |
5.737600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.55370161181168E-11 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
9.808000E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.16400247615911E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62814206561279E-12 |
| Normal-vs-Age(81-100Yrs) |
2.595000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.569800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.138050E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.048600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.633200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.834000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.456200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.271780E-02 |
| Classical-VS-Follicular |
7.110800E-01 |
| Classical-VS-Other |
3.071600E-01 |
| Classical-VS-Normal |
1.86340054497691E-10 |
| Tall-VS-Follicular |
5.472500E-02 |
| Tall-VS-Other |
1.237620E-01 |
| Tall-VS-Normal |
5.4873883215123E-12 |
| Follicular-VS-Other |
1.143650E-01 |
| Follicular-VS-Normal |
9.34979982325501E-10 |
| Other-VS-Normal |
2.264000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.66533453693773E-15 |
| Normal-vs-N1 |
5.2456927690514E-12 |
| N0-vs-N1 |
5.835000E-01 |
|
|
